ArriVent BioPharma, Inc. Common Stock (AVBP) 10-Year Financial Performance & Capital Metrics

AVBP • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Show more

Revenue $0
EBITDA -$80M -7.9%
Net Income -$80M -16.1%
EPS (Diluted) -2.56 -18.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -39.36% +7.5%
ROIC -76.56% +91.5%
Debt/Equity 0.00 -67.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-86.8%

EPS CAGR

10Y-

5Y-

3Y-

TTM-75.93%

ROCE

10Y Avg-36.8%

5Y Avg-36.8%

3Y Avg-42.03%

Latest-46.1%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0
Revenue Growth %	-	-	-	-
Cost of Goods Sold+	0	0	0	0
COGS % of Revenue	-	-	-	-
Gross Profit+	0	0	0	0
Gross Margin %	-	-	-	-
Gross Profit Growth %	-	-	-	-
Operating Expenses+	8.7M	36.91M	74.59M	94.31M
OpEx % of Revenue	-	-	-	-
Selling, General & Admin	2.26M	6.47M	9.71M	15.3M
SG&A % of Revenue	-	-	-	-
Research & Development	6.43M	30.43M	64.88M	79M
R&D % of Revenue	-	-	-	-
Other Operating Expenses	0	0	0	0
Operating Income+	-8.7M	-36.91M	-74.59M	-94.31M
Operating Margin %	-	-	-	-
Operating Income Growth %	-	-3.24%	-1.02%	-0.26%
EBITDA+	-51.61M	0	-74.59M	-80.49M
EBITDA Margin %	-	-	-	-
EBITDA Growth %	-	1%	-	-0.08%
D&A (Non-Cash Add-back)	0	36.91M	0	0
EBIT	-51.61M	-36.91M	-74.59M	-80.49M
Net Interest Income+	0	0	5.26M	13.82M
Interest Income	0	0	5.26M	13.82M
Interest Expense	0	0	0	0
Other Income/Expense	-42.91M	0	5.26M	13.82M
Pretax Income+	-51.61M	-36.91M	-69.33M	-80.49M
Pretax Margin %	-	-	-	-
Income Tax+	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%
Net Income+	-51.61M	-36.91M	-69.33M	-80.49M
Net Margin %	-	-	-	-
Net Income Growth %	-	0.28%	-0.88%	-0.16%
Net Income (Continuing)	-51.61M	-36.91M	-69.33M	-80.49M
Discontinued Operations	0	0	0	0
Minority Interest	0	0	0	0
EPS (Diluted)+	-40.44	-1.10	-2.17	-2.56
EPS Growth %	-	0.97%	-0.97%	-0.18%
EPS (Basic)	-40.44	-1.10	-2.17	-2.56
Diluted Shares Outstanding	1.28M	33.49M	31.96M	31.47M
Basic Shares Outstanding	1.28M	33.49M	31.96M	31.47M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	42.95M	182.62M	159.97M	226.98M
Cash & Short-Term Investments	37.28M	163.37M	150.39M	218.86M
Cash Only	37.28M	163.37M	150.39M	74.29M
Short-Term Investments	0	0	0	144.57M
Accounts Receivable	0	0	0	500K
Days Sales Outstanding	-	-	-	-
Inventory	0	0	0	0
Days Inventory Outstanding	-	-	-	-
Other Current Assets	5.64M	18.92M	9.21M	0
Total Non-Current Assets+	87K	211K	3.13M	47.96M
Property, Plant & Equipment	0	139K	291K	154K
Fixed Asset Turnover	-	-	-	-
Goodwill	0	0	0	0
Intangible Assets	0	0	0	0
Long-Term Investments	0	0	0	47.68M
Other Non-Current Assets	87K	72K	2.84M	126K
Total Assets+	43.04M	182.83M	163.1M	274.94M
Asset Turnover	-	-	-	-
Asset Growth %	-	3.25%	-0.11%	0.69%
Total Current Liabilities+	1.82M	8.36M	11.62M	17.27M
Accounts Payable	293K	3.09M	4.53M	3.78M
Days Payables Outstanding	-	-	-	-
Short-Term Debt	0	0	0	0
Deferred Revenue (Current)	0	0	0	0
Other Current Liabilities	0	0	0	4.16M
Current Ratio	23.63x	21.84x	13.76x	13.14x
Quick Ratio	23.63x	21.84x	13.76x	13.14x
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	0	11K	177K	14K
Long-Term Debt	0	0	0	0
Capital Lease Obligations	0	11K	177K	14K
Deferred Tax Liabilities	0	0	0	0
Other Non-Current Liabilities	0	0	0	0
Total Liabilities	1.82M	8.37M	11.8M	17.29M
Total Debt+	0	139K	317K	176K
Net Debt	-37.28M	-163.23M	-150.07M	-74.12M
Debt / Equity	-	0.00x	0.00x	0.00x
Debt / EBITDA	-	-	-	-
Net Debt / EBITDA	-	-	-	-
Interest Coverage	-	-	-	-
Total Equity+	41.22M	174.46M	151.3M	257.65M
Equity Growth %	-	3.23%	-0.13%	0.7%
Book Value per Share	32.30	5.21	4.73	8.19
Total Shareholders' Equity	41.22M	174.46M	151.3M	257.65M
Common Stock	0	0	0	3K
Retained Earnings	-51.61M	-88.51M	-157.84M	-238.33M
Treasury Stock	0	0	0	0
Accumulated OCI	-2K	0	0	-211K
Minority Interest	0	0	0	0

Cash Flow

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-12.59M	-43.63M	-55.84M	-70.21M
Operating CF Margin %	-	-	-	-
Operating CF Growth %	-	-2.47%	-0.28%	-0.26%
Net Income	-51.61M	-36.91M	-69.33M	-80.49M
Depreciation & Amortization	0	0	0	0
Stock-Based Compensation	0	424K	895K	3.21M
Deferred Taxes	0	0	0	0
Other Non-Cash Items	42.96M	0	0	0
Working Capital Changes	-3.94M	-7.15M	12.6M	7.07M
Change in Receivables	0	0	0	0
Change in Inventory	0	0	0	0
Change in Payables	293K	2.8M	1.38M	-751K
Cash from Investing+	-40M	0	0	-192.47M
Capital Expenditures	0	0	0	0
CapEx % of Revenue	-	-	-	-
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	-40M	0	0	0
Cash from Financing+	89.87M	169.72M	42.86M	186.58M
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	0	15K	-2.06M	631K
Net Change in Cash	-	-	-	-
Free Cash Flow+	-12.59M	-43.63M	-55.84M	-70.21M
FCF Margin %	-	-	-	-
FCF Growth %	-	-2.47%	-0.28%	-0.26%
FCF per Share	-9.86	-1.30	-1.75	-2.23
FCF Conversion (FCF/Net Income)	0.24x	1.18x	0.81x	0.87x
Interest Paid	0	0	0	0
Taxes Paid	0	0	0	0

Key Ratios

Metric	2021	2022	2023	2024
Return on Equity (ROE)	-125.19%	-34.22%	-42.57%	-39.36%
Return on Invested Capital (ROIC)	-	-364.92%	-898.39%	-76.56%
Debt / Equity	-	0.00x	0.00x	0.00x
FCF Conversion	0.24x	1.18x	0.81x	0.87x

Frequently Asked Questions

Growth & Financials

ArriVent BioPharma, Inc. Common Stock (AVBP) grew revenue by 0.0% over the past year. Growth has been modest.

ArriVent BioPharma, Inc. Common Stock (AVBP) reported a net loss of $151.4M for fiscal year 2024.

Dividend & Returns

ArriVent BioPharma, Inc. Common Stock (AVBP) has a return on equity (ROE) of -39.4%. Negative ROE indicates the company is unprofitable.

ArriVent BioPharma, Inc. Common Stock (AVBP) had negative free cash flow of $146.1M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener